Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль микроРНК в диагностике сердечно-сосудистых заболеваний у пациентов с ожирением
Швангирадзе Т.А., Бондаренко И.З., Трошина Е.А. Роль микроРНК в диагностике сердечно-сосудистых заболеваний у пациентов с ожирением. Consilium Medicum. 2021; 23 (4): 358–362. DOI: 10.26442/20751753.2021.4.200827
________________________________________________
Shvangiradze TA, Bondarenko IZ, Troshina EA. The role of microRNA in the diagnosis of cardiovascular diseases in obese patients. Consilium Medicum. 2021; 23 (4): 358–362. DOI: 10.26442/20751753.2021.4.200827
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Ожирение остается глобальной проблемой современного общества и часто ассоциируется с повышенным риском сердечно-сосудистых заболеваний (ССЗ). Продолжается поиск высокоспецифичных и высокочувствительных биомаркеров ССЗ. В настоящее время активно проводятся исследования, направленные на изучение микроРНК (миРНК) в качестве новых потенциальных маркеров ССЗ. Роль миРНК описана для различных звеньев патогенеза ССЗ. Эндотелиальная дисфункция считается начальным этапом патогенеза многих ССЗ и атеросклероза в частности. Изменение экспрессии ряда миРНК ассоциируется с развитием эндотелиальной дисфункции, в том числе и при ожирении. Некоторые миРНК рассматриваются как потенциальные терапевтические мишени. Дальнейшее изучение роли миРНК в патогенезе ССЗ позволит персонифицировать стратегию по выделению группы пациентов с более тяжелым прогнозом.
Ключевые слова: ожирение, атеросклероз, микроРНК, сердечно-сосудистые заболевания, эндотелиальная дисфункция
Ключевые слова: ожирение, атеросклероз, микроРНК, сердечно-сосудистые заболевания, эндотелиальная дисфункция
________________________________________________
Obesity remains a global problem in modern society. It is commonly associated with an increased risk of cardiovascular diseases (CVD). The search for specific and sensitive biomarkers of CVD continues. Currently, a lot of studies focused on the potential role of microRNA (miRNA) in CVD development and progression. MiRNAs are involved in various pathological disorders associated with CVD. Endothelial dysfunction is considered as the initial step in the pathogenesis of many CVD, and atherosclerosis in particular. Altered expression of several miRNAs is associated with the development of endothelial dysfunction. Some miRNAs are considered as potential therapeutic targets. Further studies to evaluate the role of miRNAs in the pathogenesis of CVD are needed. It will improve the diagnosis and treatment of CVD in patients with obesity.
Keywords: obesity, atherosclerosis, microRNA, cardiovascular diseases, endothelial dysfunction
Полный текст
Список литературы
1. Khan LK, Bowman BA. Obesity: A major global public health problem. Annu Rev Nutr. 1999;19. DOI:10.1146/annurev.nutr.19.1.0
2. Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121. DOI:10.3810/pgm.2009.11.2074
3. Zhou SS, Jin JP, Wang JQ, et al. MiRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges review-article. Acta Pharmacol Sin. 2018;39. DOI:10.1038/aps.2018.30
4. Jonk AM, Houben AJHM, De Jongh RT, et al. Microvascular dysfunction in obesity: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology. 2007;22. DOI:10.1152/physiol.00012.2007
5. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007;116. DOI:10.1161/CIRCULATIONAHA.106.681304
6. Vanhoutte PM. Endothelial dysfunction – The first step toward coronary arteriosclerosis. Circ J. 2009;73. DOI:10.1253/circj.CJ-08-1169
7. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes Res. 2003;11. DOI:10.1038/oby.2003.174
8. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34. DOI:10.1016/j.cjca.2017.12.005
9. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12. DOI:10.1038/nrg3074
10. Tüfekci KU, Öner MG, Meuwissen RLJ, Genç Ş. The role of microRNAs in human diseases. Methods Mol Biol. 2014;1107. DOI:10.1007/978-1-62703-748-8_3
11. Pordzik J, Jakubik D, Jarosz-Popek J, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: Bioinformatic analysis and review. Cardiovasc Diabetol. 2019;18. DOI:10.1186/s12933-019-0918-x
12. Швангирадзе Т.А., Бондаренко И.З., Трошина Е.А., Шестакова М.В. МикроРНК в диагностике сердечно-сосудистых заболеваний, ассоциированных с сахарным диабетом 2-го типа и ожирением. Терапевтический архив. 2016;88(10):87-92 [Shvangiradze TA, Bondarenko IZ, Troshina EA, Shestakova MV. MiRNAs in the diagnosis of cardiovascular diseases associated with type 2 diabetes mellitus and obesity. Terapevticheskii Arkhiv (Ter. Arkh.). 2016;88(10):87-92 (in Russian)]. DOI:10.17116/terarkh201688687-92
13. Iacomino G, Siani A. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 2017;12. DOI:10.1186/s12263-017-0577-z
14. Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47. DOI:10.1093/nar/gky1141
15. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of Mammalian MicroRNA Targets. Cell. 2003;115. DOI:10.1016/S0092-8674(03)01018-3
16. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23. DOI:10.1161/01.ATV.0000051384.43104.FC
17. Lerman A, Burnett JC. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992;86.
18. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation. 2005;111.
DOI:10.1161/01.CIR.0000153339.27064.14
19. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3. DOI:10.1096/fasebj.3.1.2642868
20. Epstein FH, Vane JR, Änggård EE, Botting RM. Regulatory Functions of the Vascular Endothelium. N Engl J Med. 1990;323. DOI:10.1056/nejm199007053230106
21. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15.
DOI:10.1097/01.ASN.0000132474.50966.DA
22. Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology. 2008;15. DOI:10.1016/j.pathophys.2008.04.007
23. Avogaro A, De Kreutzenberg SV. Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta. 2005;360. DOI:10.1016/j.cccn.2005.04.020
24. Gamez-Mendez AM, Vargas-Robles H, Ríos A, Escalante B. Oxidative stress-dependent coronary endothelial dysfunction in obese mice. PLoS One. 2015;10. DOI:10.1371/journal.pone.0138609
25. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11. DOI:10.1038/sj.cdd.4401451
26. Kaplon RE, Chung E, Reese L, et al. Activation of the unfolded protein response in vascular endothelial cells of Nondiabetic obese adults. J Clin Endocrinol Metab. 2013;98.
DOI:10.1210/jc.2013-1841
27. Bharath LP, Cho JM, Park SK, et al. Endothelial Cell Autophagy Maintains Shear Stress-Induced Nitric Oxide Generation via Glycolysis-Dependent Purinergic Signaling to Endothelial Nitric Oxide Synthase. Arterioscler Thromb Vasc Biol. 2017;37. DOI:10.1161/ATVBAHA.117.309510
28. Iantorno M, Campia U, Di Daniele N, et al. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014;28.
29. Zhang W, Yan L, Li Y, et al. Roles of miRNA-24 in regulating endothelial nitric oxide synthase expression and vascular endothelial cell proliferation. Mol Cell Biochem. 2015;405. DOI:10.1007/s11010-015-2418-y
30. Li HT, Wang J, Li SF, et al. Upregulation of microRNA-24 causes vasospasm following subarachnoid hemorrhage by suppressing the expression of endothelial nitric oxide synthase. Mol Med Rep. 2018;18. DOI:10.3892/mmr.2018.9050
31. Zheng Y, Li Y, Liu G,et al. MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-α3 and regulating inflammatory responses. Exp Ther Med. 2018;15. DOI:10.3892/etm.2017.5355
32. Chen W, Ou HS. Regulation of miR-24 on vascular endothelial cell function and its role in the development of cardiovascular disease. Sheng Li Xue Bao. 2016;68.
33. Ren K, Zhu X, Zheng Z, et al. MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I. Atherosclerosis. 2018;270. DOI:10.1016/j.atherosclerosis.2018.01.045
34. Sun HX, Zeng DY, Li RT, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60. DOI:10.1161/HYPERTENSIONAHA.112.197301
35. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14. DOI:10.1007/s11154-012-9229-1
36. Sayed D, Abdellatif M. AKT-ing via microRNA. Cell Cycle. 2010;9. DOI:10.4161/cc.9.16.12634
37. Sun X, Lin J, Zhang Y, et al. MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res. 2016;118. DOI:10.1161/CIRCRESAHA.115.308166
38. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38. DOI:10.1038/ng1725
39. Sayed D, Abdellatif M. Micrornas in development and disease. Physiol Rev. 2011;91.
DOI:10.1152/physrev.00006.2010
40. Thum T, Catalucci D, Bauersachs J. MicroRNAs: Novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79. DOI:10.1093/cvr/cvn137
41. Maegdefessel L. The emerging role of microRNAs in cardiovascular disease. J Intern Med. 2014;276. DOI:10.1111/joim.12298
42. Arunachalam G, Upadhyay R, Ding H, Triggle CR. MicroRNA signature and cardiovascular dysfunction. J Cardiovasc Pharmacol. 2015;65. DOI:10.1097/FJC.0000000000000178
43. da Silva DCP, Carneiro FD, Almeida KC de, Bottino CFDS. Role of miRNAs on the pathophysiology of cardiovascular diseases. Arq Bras Cardiol. 2018;111. DOI:10.5935/abc.20180215
44. Halushka PV, Goodwin AJ, MKH. Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers. Annu Rev Pathol. 2019;24:211-38. DOI:10.1146/annurev-pathmechdis-012418-012827
45. Çakmak HA, Demir M. Microrna and cardiovascular diseases. Balkan Med J. 2020;37:60-71. DOI:10.4274/balkanmedj.galenos.2020.2020.1.94
46. Liu X, Dong Y, Chen S, et al. Circulating MicroRNA-146a and MicroRNA-21 Predict Left Ventricular Remodeling after ST-Elevation Myocardial Infarction. Cardiol. 2015;132. DOI:10.1159/000437090
47. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51. DOI:10.1016/j.yjmcc.2011.07.011
48. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015;277. DOI:10.1111/joim.12183
49. Goretti E, Vausort M, Wagner DR, Devaux Y. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction. Int J Cardiol. 2013;168. DOI:10.1016/j.ijcard.2013.06.092
50. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31:659–66. DOI:10.1093/eurheartj/ehq013
51. Shvangiradze T, Bondarenko I, Troshina E, et al. Profile of microRNAs associated with coronary heart disease in patients with type 2 diabetes. Obe Metab. 2016;13:34. DOI:10.14341/omet2016434-38
2. Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121. DOI:10.3810/pgm.2009.11.2074
3. Zhou SS, Jin JP, Wang JQ, et al. MiRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges review-article. Acta Pharmacol Sin. 2018;39. DOI:10.1038/aps.2018.30
4. Jonk AM, Houben AJHM, De Jongh RT, et al. Microvascular dysfunction in obesity: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology. 2007;22. DOI:10.1152/physiol.00012.2007
5. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007;116. DOI:10.1161/CIRCULATIONAHA.106.681304
6. Vanhoutte PM. Endothelial dysfunction – The first step toward coronary arteriosclerosis. Circ J. 2009;73. DOI:10.1253/circj.CJ-08-1169
7. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes Res. 2003;11. DOI:10.1038/oby.2003.174
8. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34. DOI:10.1016/j.cjca.2017.12.005
9. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12. DOI:10.1038/nrg3074
10. Tüfekci KU, Öner MG, Meuwissen RLJ, Genç Ş. The role of microRNAs in human diseases. Methods Mol Biol. 2014;1107. DOI:10.1007/978-1-62703-748-8_3
11. Pordzik J, Jakubik D, Jarosz-Popek J, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: Bioinformatic analysis and review. Cardiovasc Diabetol. 2019;18. DOI:10.1186/s12933-019-0918-x
12. Швангирадзе Т.А., Бондаренко И.З., Трошина Е.А., Шестакова М.В. МикроРНК в диагностике сердечно-сосудистых заболеваний, ассоциированных с сахарным диабетом 2-го типа и ожирением. Терапевтический архив. 2016;88(10):87-92 [Shvangiradze TA, Bondarenko IZ, Troshina EA, Shestakova MV. MiRNAs in the diagnosis of cardiovascular diseases associated with type 2 diabetes mellitus and obesity. Terapevticheskii Arkhiv (Ter. Arkh.). 2016;88(10):87-92 (in Russian)]. DOI:10.17116/terarkh201688687-92
13. Iacomino G, Siani A. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 2017;12. DOI:10.1186/s12263-017-0577-z
14. Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47. DOI:10.1093/nar/gky1141
15. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of Mammalian MicroRNA Targets. Cell. 2003;115. DOI:10.1016/S0092-8674(03)01018-3
16. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23. DOI:10.1161/01.ATV.0000051384.43104.FC
17. Lerman A, Burnett JC. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992;86.
18. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation. 2005;111.
DOI:10.1161/01.CIR.0000153339.27064.14
19. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3. DOI:10.1096/fasebj.3.1.2642868
20. Epstein FH, Vane JR, Änggård EE, Botting RM. Regulatory Functions of the Vascular Endothelium. N Engl J Med. 1990;323. DOI:10.1056/nejm199007053230106
21. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15.
DOI:10.1097/01.ASN.0000132474.50966.DA
22. Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology. 2008;15. DOI:10.1016/j.pathophys.2008.04.007
23. Avogaro A, De Kreutzenberg SV. Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta. 2005;360. DOI:10.1016/j.cccn.2005.04.020
24. Gamez-Mendez AM, Vargas-Robles H, Ríos A, Escalante B. Oxidative stress-dependent coronary endothelial dysfunction in obese mice. PLoS One. 2015;10. DOI:10.1371/journal.pone.0138609
25. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11. DOI:10.1038/sj.cdd.4401451
26. Kaplon RE, Chung E, Reese L, et al. Activation of the unfolded protein response in vascular endothelial cells of Nondiabetic obese adults. J Clin Endocrinol Metab. 2013;98.
DOI:10.1210/jc.2013-1841
27. Bharath LP, Cho JM, Park SK, et al. Endothelial Cell Autophagy Maintains Shear Stress-Induced Nitric Oxide Generation via Glycolysis-Dependent Purinergic Signaling to Endothelial Nitric Oxide Synthase. Arterioscler Thromb Vasc Biol. 2017;37. DOI:10.1161/ATVBAHA.117.309510
28. Iantorno M, Campia U, Di Daniele N, et al. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014;28.
29. Zhang W, Yan L, Li Y, et al. Roles of miRNA-24 in regulating endothelial nitric oxide synthase expression and vascular endothelial cell proliferation. Mol Cell Biochem. 2015;405. DOI:10.1007/s11010-015-2418-y
30. Li HT, Wang J, Li SF, et al. Upregulation of microRNA-24 causes vasospasm following subarachnoid hemorrhage by suppressing the expression of endothelial nitric oxide synthase. Mol Med Rep. 2018;18. DOI:10.3892/mmr.2018.9050
31. Zheng Y, Li Y, Liu G,et al. MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-α3 and regulating inflammatory responses. Exp Ther Med. 2018;15. DOI:10.3892/etm.2017.5355
32. Chen W, Ou HS. Regulation of miR-24 on vascular endothelial cell function and its role in the development of cardiovascular disease. Sheng Li Xue Bao. 2016;68.
33. Ren K, Zhu X, Zheng Z, et al. MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I. Atherosclerosis. 2018;270. DOI:10.1016/j.atherosclerosis.2018.01.045
34. Sun HX, Zeng DY, Li RT, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60. DOI:10.1161/HYPERTENSIONAHA.112.197301
35. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14. DOI:10.1007/s11154-012-9229-1
36. Sayed D, Abdellatif M. AKT-ing via microRNA. Cell Cycle. 2010;9. DOI:10.4161/cc.9.16.12634
37. Sun X, Lin J, Zhang Y, et al. MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res. 2016;118. DOI:10.1161/CIRCRESAHA.115.308166
38. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38. DOI:10.1038/ng1725
39. Sayed D, Abdellatif M. Micrornas in development and disease. Physiol Rev. 2011;91.
DOI:10.1152/physrev.00006.2010
40. Thum T, Catalucci D, Bauersachs J. MicroRNAs: Novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79. DOI:10.1093/cvr/cvn137
41. Maegdefessel L. The emerging role of microRNAs in cardiovascular disease. J Intern Med. 2014;276. DOI:10.1111/joim.12298
42. Arunachalam G, Upadhyay R, Ding H, Triggle CR. MicroRNA signature and cardiovascular dysfunction. J Cardiovasc Pharmacol. 2015;65. DOI:10.1097/FJC.0000000000000178
43. da Silva DCP, Carneiro FD, Almeida KC de, Bottino CFDS. Role of miRNAs on the pathophysiology of cardiovascular diseases. Arq Bras Cardiol. 2018;111. DOI:10.5935/abc.20180215
44. Halushka PV, Goodwin AJ, MKH. Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers. Annu Rev Pathol. 2019;24:211-38. DOI:10.1146/annurev-pathmechdis-012418-012827
45. Çakmak HA, Demir M. Microrna and cardiovascular diseases. Balkan Med J. 2020;37:60-71. DOI:10.4274/balkanmedj.galenos.2020.2020.1.94
46. Liu X, Dong Y, Chen S, et al. Circulating MicroRNA-146a and MicroRNA-21 Predict Left Ventricular Remodeling after ST-Elevation Myocardial Infarction. Cardiol. 2015;132. DOI:10.1159/000437090
47. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51. DOI:10.1016/j.yjmcc.2011.07.011
48. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015;277. DOI:10.1111/joim.12183
49. Goretti E, Vausort M, Wagner DR, Devaux Y. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction. Int J Cardiol. 2013;168. DOI:10.1016/j.ijcard.2013.06.092
50. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31:659–66. DOI:10.1093/eurheartj/ehq013
51. Shvangiradze T, Bondarenko I, Troshina E, et al. Profile of microRNAs associated with coronary heart disease in patients with type 2 diabetes. Obe Metab. 2016;13:34. DOI:10.14341/omet2016434-38
________________________________________________
1. Khan LK, Bowman BA. Obesity: A major global public health problem. Annu Rev Nutr. 1999;19. DOI:10.1146/annurev.nutr.19.1.0
2. Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121. DOI:10.3810/pgm.2009.11.2074
3. Zhou SS, Jin JP, Wang JQ, et al. MiRNAS in cardiovascular diseases: Potential biomarkers, therapeutic targets and challenges review-article. Acta Pharmacol Sin. 2018;39. DOI:10.1038/aps.2018.30
4. Jonk AM, Houben AJHM, De Jongh RT, et al. Microvascular dysfunction in obesity: A potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology. 2007;22. DOI:10.1152/physiol.00012.2007
5. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007;116. DOI:10.1161/CIRCULATIONAHA.106.681304
6. Vanhoutte PM. Endothelial dysfunction – The first step toward coronary arteriosclerosis. Circ J. 2009;73. DOI:10.1253/circj.CJ-08-1169
7. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes Res. 2003;11. DOI:10.1038/oby.2003.174
8. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34. DOI:10.1016/j.cjca.2017.12.005
9. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12. DOI:10.1038/nrg3074
10. Tüfekci KU, Öner MG, Meuwissen RLJ, Genç Ş. The role of microRNAs in human diseases. Methods Mol Biol. 2014;1107. DOI:10.1007/978-1-62703-748-8_3
11. Pordzik J, Jakubik D, Jarosz-Popek J, et al. Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: Bioinformatic analysis and review. Cardiovasc Diabetol. 2019;18. DOI:10.1186/s12933-019-0918-x
12. Shvangiradze TA, Bondarenko IZ, Troshina EA, Shestakova MV. MiRNAs in the diagnosis of cardiovascular diseases associated with type 2 diabetes mellitus and obesity. Terapevticheskii Arkhiv (Ter. Arkh.). 2016;88(10):87-92 (in Russian)
DOI:10.17116/terarkh201688687-92
13. Iacomino G, Siani A. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 2017;12. DOI:10.1186/s12263-017-0577-z
14. Kozomara A, Birgaoanu M, Griffiths-Jones S. MiRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47. DOI:10.1093/nar/gky1141
15. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of Mammalian MicroRNA Targets. Cell. 2003;115. DOI:10.1016/S0092-8674(03)01018-3
16. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23. DOI:10.1161/01.ATV.0000051384.43104.FC
17. Lerman A, Burnett JC. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992;86.
18. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation. 2005;111.
DOI:10.1161/01.CIR.0000153339.27064.14
19. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989;3. DOI:10.1096/fasebj.3.1.2642868
20. Epstein FH, Vane JR, Änggård EE, Botting RM. Regulatory Functions of the Vascular Endothelium. N Engl J Med. 1990;323. DOI:10.1056/nejm199007053230106
21. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15.
DOI:10.1097/01.ASN.0000132474.50966.DA
22. Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology. 2008;15. DOI:10.1016/j.pathophys.2008.04.007
23. Avogaro A, De Kreutzenberg SV. Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta. 2005;360. DOI:10.1016/j.cccn.2005.04.020
24. Gamez-Mendez AM, Vargas-Robles H, Ríos A, Escalante B. Oxidative stress-dependent coronary endothelial dysfunction in obese mice. PLoS One. 2015;10. DOI:10.1371/journal.pone.0138609
25. Austin RC, Lentz SR, Werstuck GH. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ. 2004;11. DOI:10.1038/sj.cdd.4401451
26. Kaplon RE, Chung E, Reese L, et al. Activation of the unfolded protein response in vascular endothelial cells of Nondiabetic obese adults. J Clin Endocrinol Metab. 2013;98.
DOI:10.1210/jc.2013-1841
27. Bharath LP, Cho JM, Park SK, et al. Endothelial Cell Autophagy Maintains Shear Stress-Induced Nitric Oxide Generation via Glycolysis-Dependent Purinergic Signaling to Endothelial Nitric Oxide Synthase. Arterioscler Thromb Vasc Biol. 2017;37. DOI:10.1161/ATVBAHA.117.309510
28. Iantorno M, Campia U, Di Daniele N, et al. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014;28.
29. Zhang W, Yan L, Li Y, et al. Roles of miRNA-24 in regulating endothelial nitric oxide synthase expression and vascular endothelial cell proliferation. Mol Cell Biochem. 2015;405. DOI:10.1007/s11010-015-2418-y
30. Li HT, Wang J, Li SF, et al. Upregulation of microRNA-24 causes vasospasm following subarachnoid hemorrhage by suppressing the expression of endothelial nitric oxide synthase. Mol Med Rep. 2018;18. DOI:10.3892/mmr.2018.9050
31. Zheng Y, Li Y, Liu G,et al. MicroRNA-24 inhibits the proliferation and migration of endothelial cells in patients with atherosclerosis by targeting importin-α3 and regulating inflammatory responses. Exp Ther Med. 2018;15. DOI:10.3892/etm.2017.5355
32. Chen W, Ou HS. Regulation of miR-24 on vascular endothelial cell function and its role in the development of cardiovascular disease. Sheng Li Xue Bao. 2016;68.
33. Ren K, Zhu X, Zheng Z, et al. MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I. Atherosclerosis. 2018;270. DOI:10.1016/j.atherosclerosis.2018.01.045
34. Sun HX, Zeng DY, Li RT, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60. DOI:10.1161/HYPERTENSIONAHA.112.197301
35. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14. DOI:10.1007/s11154-012-9229-1
36. Sayed D, Abdellatif M. AKT-ing via microRNA. Cell Cycle. 2010;9. DOI:10.4161/cc.9.16.12634
37. Sun X, Lin J, Zhang Y, et al. MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res. 2016;118. DOI:10.1161/CIRCRESAHA.115.308166
38. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006;38. DOI:10.1038/ng1725
39. Sayed D, Abdellatif M. Micrornas in development and disease. Physiol Rev. 2011;91.
DOI:10.1152/physrev.00006.2010
40. Thum T, Catalucci D, Bauersachs J. MicroRNAs: Novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79. DOI:10.1093/cvr/cvn137
41. Maegdefessel L. The emerging role of microRNAs in cardiovascular disease. J Intern Med. 2014;276. DOI:10.1111/joim.12298
42. Arunachalam G, Upadhyay R, Ding H, Triggle CR. MicroRNA signature and cardiovascular dysfunction. J Cardiovasc Pharmacol. 2015;65. DOI:10.1097/FJC.0000000000000178
43. da Silva DCP, Carneiro FD, Almeida KC de, Bottino CFDS. Role of miRNAs on the pathophysiology of cardiovascular diseases. Arq Bras Cardiol. 2018;111. DOI:10.5935/abc.20180215
44. Halushka PV, Goodwin AJ, MKH. Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers. Annu Rev Pathol. 2019;24:211-38. DOI:10.1146/annurev-pathmechdis-012418-012827
45. Çakmak HA, Demir M. Microrna and cardiovascular diseases. Balkan Med J. 2020;37:60-71. DOI:10.4274/balkanmedj.galenos.2020.2020.1.94
46. Liu X, Dong Y, Chen S, et al. Circulating MicroRNA-146a and MicroRNA-21 Predict Left Ventricular Remodeling after ST-Elevation Myocardial Infarction. Cardiol. 2015;132. DOI:10.1159/000437090
47. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51. DOI:10.1016/j.yjmcc.2011.07.011
48. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015;277. DOI:10.1111/joim.12183
49. Goretti E, Vausort M, Wagner DR, Devaux Y. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction. Int J Cardiol. 2013;168. DOI:10.1016/j.ijcard.2013.06.092
50. Wang GK, Zhu JQ, Zhang JT, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31:659–66. DOI:10.1093/eurheartj/ehq013
51. Shvangiradze T, Bondarenko I, Troshina E, et al. Profile of microRNAs associated with coronary heart disease in patients with type 2 diabetes. Obe Metab. 2016;13:34. DOI:10.14341/omet2016434-38
Авторы
Т.А. Швангирадзе*1, И.З. Бондаренко2, Е.А. Трошина2
1 АО «Клиника К+31», Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*teona.endo@gmail.com
1 АО «Клиника К+31», Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия
*teona.endo@gmail.com
________________________________________________
Teona A. Shvangiradze*1, Irina Z. Bondarenko2, Ekaterina A. Troshina2
1 Clinic K+31, Moscow, Russia;
2 Endocrinology Research Centre, Moscow, Russia
*teona.endo@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.